GlassScriptPhysician profile
Jeremy D Webb
NPI 1609307255
$4,031.11
in general payments reported to CMS, 2019-2025
28 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $662 · 2022: $432 · 2023: $597 · 2024: $1,033 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,081.29 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $479.53 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $469.97 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $324.75 | 2022-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.65 | 2020-2024 | Jardiance |
| Amgen INC. | $222.00 | 2020-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $160.86 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $148.51 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $95.81 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.05 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $79.04 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $77.75 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $73.93 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $59.71 | 2024-2025 | Qelbree |
| Lundbeck LLC | $57.86 | 2023-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $50.90 | 2025 | Jornay Pm |
| Philips North America LLC | $46.10 | 2024-2025 | Ecc Solutions, (Ck7) Extended Holter |
| Phathom Pharmaceuticals, INC. | $45.23 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $34.23 | 2021-2025 | Spravato |
| Dexcom, INC. | $34.08 | 2022 | |
| Tris Pharma INC | $33.49 | 2025 | Dyanavel Xr |
| Exact Sciences Corporation | $32.10 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $30.23 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $12.86 | 2021 | |
| Adlon Therapeutics L.P. | $11.36 | 2021 | |
| Abbott Laboratories | $11.33 | 2021 | |
| Insulet Corporation | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.